Caliway Biopharmaceuticals (6919.TW)

Executive Summary

Caliway Biopharmaceuticals is a clinical-stage biotechnology company based in Taiwan, publicly traded on the Taipei Exchange (6919.TW). The company focuses on developing novel small-molecule therapies for non-invasive aesthetic and medical applications. Its lead candidate, CBL-514, is designed for localized fat reduction and lipoma treatment. Caliway has completed multiple Phase 2 trials demonstrating safety and efficacy in subcutaneous fat reduction and cellulite. The company is currently advancing CBL-514 into a Phase 3 trial for subcutaneous fat reduction (NCT07140939), which began enrollment in September 2025, with estimated completion in September 2026. Additionally, a Phase 2 trial for Dercum's disease (NCT06303570) is recruiting, expected to complete in April 2026. With a market cap of approximately $155 billion (estimated), Caliway represents a high-risk, high-reward opportunity in the aesthetic biotech space. Key upcoming milestones include Phase 3 data readout and potential regulatory filings, which could drive significant value if positive.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Top-Line Data for CBL-514 in Subcutaneous Fat Reduction60% success
• Q2 2026Phase 2 Data for CBL-514 in Dercum's Disease40% success